SDIC Chuangyi Invests in DerivMicro, a Leading Synthetic Biology Company, with WinX Capital as Exclusive Financial Advisor

Recently, SDIC Chuangyi invested in Beijing Yanwei Technology Co., Ltd., a company in the biomanufacturing sector, with WinX Capital serving as the exclusive financial advisor. This round of financing will accelerate the company’s new production capacity construction and commercialization process, facilitating the expansion of applications for its synthetic biology technologies.

Yanwei Technology, established in 2022, leverages *Rhodococcus* and *Bacillus* as its two core chassis cells, focusing on the biomanufacturing and application development of whole-cell catalysts and bio-based surfactants. Its downstream applications span oilfield chemicals, agriculture and food, daily chemicals, and medical aesthetics. Professor Huimin Yu from the Department of Chemical Engineering at Tsinghua University, co-founder of Yanwei Technology, has accumulated extensive R&D expertise in these fields. She has originally developed a highly stress-resistant and high-expression synthetic biology platform for *Rhodococcus*, as well as super cell factories for natural biosurfactants. The related technological capabilities and industrialization achievements are at an internationally leading level.

The Bacillus-derived lipid biostimulant developed by Yanwei Technology is the first of its kind to achieve commercialization globally. It significantly promotes fertilizer uptake, regulates plant metabolism and physiological status, improves soil microbial community structure and fertility, and enhances crop stress resistance. The product has demonstrated significant yield increases and quality improvements across 25 regions in China and on more than 70 crop types, offering advantages such as low effective concentration, broad applicability, high cost-effectiveness, and ease of use. Multiple pipeline products based on this chassis cell are currently in scale-up and pilot production stages, with one molecule showing promise for development into a novel antifungal biopesticide.

SDIC Chuangyi believes that following the era of chemical fertilizers, synthetic biology technology has ushered in a new chapter in plant nutrition. The novel biostimulants developed by Yanwei Technology through years of dedicated research in synthetic biology can significantly enhance crop yield and quality. The advantages of this technology have been validated over multiple years in numerous field trials across Sichuan, Ningxia, Heilongjiang, Liaoning, and other regions.

SDIC Chuangyi will support Yanwei Technology in advancing its existing R&D products and help expand its platform technologies. We look forward to Yanwei Technology bringing new options for crop nutrition, providing more efficient solutions for modern agriculture, and jointly promoting the high-quality development of China’s bio-manufacturing sector.

WinX CapitalStatement: It is a great honor to serve as the exclusive financial advisor to Yanwei Technology, facilitating its strategic investment from SDIC Chuangyi. Leveraging its internationally leading synthetic biology technology platform, Yanwei Technology has demonstrated strong innovation and commercialization potential in fields such as bio-based surfactants and novel agricultural biostimulants. With Yanwei Technology’s solid industrial layout and the capital support from SDIC Chuangyi, the company will accelerate capacity implementation and market expansion, injecting new momentum into the upgrading of China’s biomanufacturing industry.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in Healthcare for 2024,” First New Voice’s “No. 1 Financial Advisory Firm in Healthcare for 2022 and 2023,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of the “Top 100 Future Healthcare Companies (2022–2024).”